排序方式: 共有14条查询结果,搜索用时 31 毫秒
1.
Objective To study the effects of atorvastatin on contrast induced renal function change and plasma hsCRP in patients undergoing coronary angiography. Methods 120 patients who underwent coronary angiography were randomized to receive atorvastatin (20 mg/qn, n = 60) or no atorvastatin (n =60) treatment 2 to 3 days before coronary angiography. Urinary α1-MG, TRF and mALB were checked for evidence of tubular or glomendar damage at start, 1 day and 2 days after the administration of a radiocontrast agent. Serum creatinine, BUN, cystatin C and hsCRP levels were also assessed at the same time. Ccr and GFR were calculated according to Cockcroft-Ganh and GFR(ml/min) = 74. 835/Cys C1.333formulas basing on serum creatinine or cystatin C concentration. Results (1) In control group, comparison with the value before coronary angiography,urinary α1-MG, TRF and mALB or serum cystatin C and hsCRP significantly increased at day 1 after angiography (P < 0.01). In comparison to the levels at day 1 after angiography, urinary α1-MG, TRF, mALB, serum cystatin C significantly decreased at day 2 after angiography(P < 0.01), but α1-MG, cystatin C still exceeded the values before coronary angiography, TRF and mALB levels at day 2 after angiography had no significant change compared to baseline(P >0.05), hsCRP LeveL at day 2 after angiography had no significant change compared to that at day 1 after angiography (P > 0.05) too. (2) In comparison with the value before coronary angiography in atorvastatin-treated group, the levels of urinary α1-MG, TRF and mALB or serum cystatin C at day 1 and day 2 after angiography had no significant change compared to baseline(P >0.05). Serum hsCRP significantly increased at day 1 after angiography compared to baseline(P < 0.01), but it had no significant change compared to day 2 after angiography (P > 0.05). (3)To compare to the atorvastatin-treated group, the values of urinary α1-MG, TRF and mALB or Cys C and hsCRP significantly increased at day 1 after angiography in control group (P < 0.01), the values of urinary α1 -MG, cystatin C and hsCRP still significantly increased at day 2 (P < 0.01) too, but those of TRF and mALB had no significantly change at day 1 or day 2 after angiography between the two groups (P > 0.05). There was no significant change in BUN, Cr, Ccr levels before and after angiography between the two groups. Conclusions Low dose contrast induces light renal function damage. Pretreatment with atorvastatin 20 mg/qn for 2 to 3 days could significantly reduce procedural inflammatory reaction, attenuate urinary protein and the effect of degrading GFR in coronary angiography patients. 相似文献
2.
阿托伐他汀对冠心病患者冠状动脉造影术后超敏C反应蛋白的影响及其对肾功能的保护作用 总被引:1,自引:0,他引:1
目的:研究阿托伐他汀对冠心病患者行冠状动脉造影术(CAG)后超敏C反应蛋白(hsCRP)的影响及对肾功能的保护作用.方法:将行CAG确诊的84例冠心病患者随机分为治疗组(43例)或对照组(41例),治疗组于CAG前2~3 d始每晚顿服阿托伐他汀20 mg,对照组CAG前未服用阿托伐他汀及其他调脂类药.所有患者分别于CAG前,术后24 h、48 h测定血肌酐(Cr)及尿素氮(BUN);留尿标本检测尿α1-微球蛋白(α1-MG)、尿转铁蛋白(TRF)、尿微量白蛋白(mALB);测血浆胱抑素C(Cys C)、hsCRP,并分别计算出肌酐清除率(Ccr)和肾小球滤过率(GFR).结果:①对照组:与CAG前相比,CAG后24 h α1-MG、TRF、mALB、Cys C及hsCRP均有显著升高(P<0.01);与CAG后24 h比较,48 h α1-MG、TRF、mALB、Cys C均有显著降低(P<0.01),但α1-MG、Cys C仍高于CAG前水平(P<0.01),而TRF、mALB已恢复到CAG前水平(P>0.05);CAG后48 h hsCRP与CAG前相比无明显变化(P>0.05).②治疗组:与CAG前比较,CAG后24 h、48 h α1-MG、TRF、mALB、Cys C均无明显变化(P>0.05);CAG后24 h hsCRP显著升高(P<0.01);CAG后48 h hsCRP与CAG前比无明显变化(P>0.05).③与治疗组相比较:对照组CAG后24 h α1-MG、TRF、mALB、Cys C及hsCRP均显著升高(P<0.01);CAG后48 h Cys C、α1-MG及hsCRP仍显著升高(P<0.01),但TRF、mALB均差异无统计学意义(P>0.05).2组CAG前、术后BUN、Cr、Ccr均无明显变化(P>0.05).结论:小剂量造影剂可造成冠心病患者CAG后出现hsCRP、CysC升高及一过性微量蛋白尿,CAG前2~3 d给服阿托伐他汀,具有改善的作用. 相似文献
3.
目的:比较替格瑞洛与氯吡格雷在氯吡格雷中间代谢类型老年急性冠状动脉综合征(ACS)患者经皮冠状动脉介入治疗(PCI)术后的预后评价。方法:选取2016-01-2018-06入住我院接受PCI的氯吡格雷基因检测为中间代谢类型的老年ACS患者132例,氯吡格雷组72例,替格瑞洛组60例。替格瑞洛组给予180 mg负荷剂量嚼服后90 mg bid维持1年;氯吡格雷组给予300/600 mg嚼服后75 mg qd维持1年。观察两组治疗前后5 d血小板抑制率和随访12个月内两组患者主要不良心血管事件(MACE)及药物不良反应。结果:治疗后第5天,替格瑞洛组血小板抑制率高于氯吡格雷组(P<0.01)。12个月内两组MACE事件差异无统计学意义(P>0.05);替格瑞洛组和氯吡格雷组总出血事件分别为10例(16.7%)和3例(4.2%)(P<0.05);两组均未发生主要出血;轻微出血为7例(11.7%)和2例(2.8%)(P<0.05);呼吸困难分别为例8例(13.3%)和1例(1.4%),差异有统计学意义(P<0.01);其中轻度呼吸困难为6例(10.0%)和1例(1... 相似文献
4.
目的探讨冠心病(CHD)患者血清尿酸与微量白蛋白尿的关系。方法 118例冠脉造影诊断为冠心病患者,入院后次日清晨测定血清尿酸(uric acid UA)、血清肌酐(Scr)、尿素氮(BUN)、总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、空腹血糖(FPG)等。留取入院后次日24小时尿液测尿微量白蛋白(mALB),mALB〈30 mg/24 h者入选mALB阴性组(男48例,女25例),平均(63.2±9.8)岁;mALB〉30mg/24 h者入选mALB阳性组(男30例,女1 5例),平均(64.7土8.7)岁。结果 mALB阳性组UA值[(398.6土35.7)μmol/L]显著高于mALB阴性组UA值[(334.8±32.4)μmol/L](P〈0.01);mALB阳性组TG、LDL-C均显著高于mALB阴性组(P〈0.05);而HDL-C显著低于mALB阴性组(P〈0.05)。在调整TG、LDL.C、HDL-C等因素后回归分析显示:UA是冠心病患者出现微量白蛋白尿的独立危险因素。结论本研究提示冠心病患者血尿酸水平与微量白蛋白尿相关。 相似文献
5.
Objective To study the effects of atorvastatin on contrast induced renal function change and plasma hsCRP in patients undergoing coronary angiography. Methods 120 patients who underwent coronary angiography were randomized to receive atorvastatin (20 mg/qn, n = 60) or no atorvastatin (n =60) treatment 2 to 3 days before coronary angiography. Urinary α1-MG, TRF and mALB were checked for evidence of tubular or glomendar damage at start, 1 day and 2 days after the administration of a radiocontrast agent. Serum creatinine, BUN, cystatin C and hsCRP levels were also assessed at the same time. Ccr and GFR were calculated according to Cockcroft-Ganh and GFR(ml/min) = 74. 835/Cys C1.333formulas basing on serum creatinine or cystatin C concentration. Results (1) In control group, comparison with the value before coronary angiography,urinary α1-MG, TRF and mALB or serum cystatin C and hsCRP significantly increased at day 1 after angiography (P < 0.01). In comparison to the levels at day 1 after angiography, urinary α1-MG, TRF, mALB, serum cystatin C significantly decreased at day 2 after angiography(P < 0.01), but α1-MG, cystatin C still exceeded the values before coronary angiography, TRF and mALB levels at day 2 after angiography had no significant change compared to baseline(P >0.05), hsCRP LeveL at day 2 after angiography had no significant change compared to that at day 1 after angiography (P > 0.05) too. (2) In comparison with the value before coronary angiography in atorvastatin-treated group, the levels of urinary α1-MG, TRF and mALB or serum cystatin C at day 1 and day 2 after angiography had no significant change compared to baseline(P >0.05). Serum hsCRP significantly increased at day 1 after angiography compared to baseline(P < 0.01), but it had no significant change compared to day 2 after angiography (P > 0.05). (3)To compare to the atorvastatin-treated group, the values of urinary α1-MG, TRF and mALB or Cys C and hsCRP significantly increased at day 1 after angiography in control group (P < 0.01), the values of urinary α1 -MG, cystatin C and hsCRP still significantly increased at day 2 (P < 0.01) too, but those of TRF and mALB had no significantly change at day 1 or day 2 after angiography between the two groups (P > 0.05). There was no significant change in BUN, Cr, Ccr levels before and after angiography between the two groups. Conclusions Low dose contrast induces light renal function damage. Pretreatment with atorvastatin 20 mg/qn for 2 to 3 days could significantly reduce procedural inflammatory reaction, attenuate urinary protein and the effect of degrading GFR in coronary angiography patients. 相似文献
6.
Objective To study the effects of atorvastatin on contrast induced renal function change and plasma hsCRP in patients undergoing coronary angiography. Methods 120 patients who underwent coronary angiography were randomized to receive atorvastatin (20 mg/qn, n = 60) or no atorvastatin (n =60) treatment 2 to 3 days before coronary angiography. Urinary α1-MG, TRF and mALB were checked for evidence of tubular or glomendar damage at start, 1 day and 2 days after the administration of a radiocontrast agent. Serum creatinine, BUN, cystatin C and hsCRP levels were also assessed at the same time. Ccr and GFR were calculated according to Cockcroft-Ganh and GFR(ml/min) = 74. 835/Cys C1.333formulas basing on serum creatinine or cystatin C concentration. Results (1) In control group, comparison with the value before coronary angiography,urinary α1-MG, TRF and mALB or serum cystatin C and hsCRP significantly increased at day 1 after angiography (P < 0.01). In comparison to the levels at day 1 after angiography, urinary α1-MG, TRF, mALB, serum cystatin C significantly decreased at day 2 after angiography(P < 0.01), but α1-MG, cystatin C still exceeded the values before coronary angiography, TRF and mALB levels at day 2 after angiography had no significant change compared to baseline(P >0.05), hsCRP LeveL at day 2 after angiography had no significant change compared to that at day 1 after angiography (P > 0.05) too. (2) In comparison with the value before coronary angiography in atorvastatin-treated group, the levels of urinary α1-MG, TRF and mALB or serum cystatin C at day 1 and day 2 after angiography had no significant change compared to baseline(P >0.05). Serum hsCRP significantly increased at day 1 after angiography compared to baseline(P < 0.01), but it had no significant change compared to day 2 after angiography (P > 0.05). (3)To compare to the atorvastatin-treated group, the values of urinary α1-MG, TRF and mALB or Cys C and hsCRP significantly increased at day 1 after angiography in control group (P < 0.01), the values of urinary α1 -MG, cystatin C and hsCRP still significantly increased at day 2 (P < 0.01) too, but those of TRF and mALB had no significantly change at day 1 or day 2 after angiography between the two groups (P > 0.05). There was no significant change in BUN, Cr, Ccr levels before and after angiography between the two groups. Conclusions Low dose contrast induces light renal function damage. Pretreatment with atorvastatin 20 mg/qn for 2 to 3 days could significantly reduce procedural inflammatory reaction, attenuate urinary protein and the effect of degrading GFR in coronary angiography patients. 相似文献
7.
Objective To study the effects of atorvastatin on contrast induced renal function change and plasma hsCRP in patients undergoing coronary angiography. Methods 120 patients who underwent coronary angiography were randomized to receive atorvastatin (20 mg/qn, n = 60) or no atorvastatin (n =60) treatment 2 to 3 days before coronary angiography. Urinary α1-MG, TRF and mALB were checked for evidence of tubular or glomendar damage at start, 1 day and 2 days after the administration of a radiocontrast agent. Serum creatinine, BUN, cystatin C and hsCRP levels were also assessed at the same time. Ccr and GFR were calculated according to Cockcroft-Ganh and GFR(ml/min) = 74. 835/Cys C1.333formulas basing on serum creatinine or cystatin C concentration. Results (1) In control group, comparison with the value before coronary angiography,urinary α1-MG, TRF and mALB or serum cystatin C and hsCRP significantly increased at day 1 after angiography (P < 0.01). In comparison to the levels at day 1 after angiography, urinary α1-MG, TRF, mALB, serum cystatin C significantly decreased at day 2 after angiography(P < 0.01), but α1-MG, cystatin C still exceeded the values before coronary angiography, TRF and mALB levels at day 2 after angiography had no significant change compared to baseline(P >0.05), hsCRP LeveL at day 2 after angiography had no significant change compared to that at day 1 after angiography (P > 0.05) too. (2) In comparison with the value before coronary angiography in atorvastatin-treated group, the levels of urinary α1-MG, TRF and mALB or serum cystatin C at day 1 and day 2 after angiography had no significant change compared to baseline(P >0.05). Serum hsCRP significantly increased at day 1 after angiography compared to baseline(P < 0.01), but it had no significant change compared to day 2 after angiography (P > 0.05). (3)To compare to the atorvastatin-treated group, the values of urinary α1-MG, TRF and mALB or Cys C and hsCRP significantly increased at day 1 after angiography in control group (P < 0.01), the values of urinary α1 -MG, cystatin C and hsCRP still significantly increased at day 2 (P < 0.01) too, but those of TRF and mALB had no significantly change at day 1 or day 2 after angiography between the two groups (P > 0.05). There was no significant change in BUN, Cr, Ccr levels before and after angiography between the two groups. Conclusions Low dose contrast induces light renal function damage. Pretreatment with atorvastatin 20 mg/qn for 2 to 3 days could significantly reduce procedural inflammatory reaction, attenuate urinary protein and the effect of degrading GFR in coronary angiography patients. 相似文献
8.
Objective To study the effects of atorvastatin on contrast induced renal function change and plasma hsCRP in patients undergoing coronary angiography. Methods 120 patients who underwent coronary angiography were randomized to receive atorvastatin (20 mg/qn, n = 60) or no atorvastatin (n =60) treatment 2 to 3 days before coronary angiography. Urinary α1-MG, TRF and mALB were checked for evidence of tubular or glomendar damage at start, 1 day and 2 days after the administration of a radiocontrast agent. Serum creatinine, BUN, cystatin C and hsCRP levels were also assessed at the same time. Ccr and GFR were calculated according to Cockcroft-Ganh and GFR(ml/min) = 74. 835/Cys C1.333formulas basing on serum creatinine or cystatin C concentration. Results (1) In control group, comparison with the value before coronary angiography,urinary α1-MG, TRF and mALB or serum cystatin C and hsCRP significantly increased at day 1 after angiography (P < 0.01). In comparison to the levels at day 1 after angiography, urinary α1-MG, TRF, mALB, serum cystatin C significantly decreased at day 2 after angiography(P < 0.01), but α1-MG, cystatin C still exceeded the values before coronary angiography, TRF and mALB levels at day 2 after angiography had no significant change compared to baseline(P >0.05), hsCRP LeveL at day 2 after angiography had no significant change compared to that at day 1 after angiography (P > 0.05) too. (2) In comparison with the value before coronary angiography in atorvastatin-treated group, the levels of urinary α1-MG, TRF and mALB or serum cystatin C at day 1 and day 2 after angiography had no significant change compared to baseline(P >0.05). Serum hsCRP significantly increased at day 1 after angiography compared to baseline(P < 0.01), but it had no significant change compared to day 2 after angiography (P > 0.05). (3)To compare to the atorvastatin-treated group, the values of urinary α1-MG, TRF and mALB or Cys C and hsCRP significantly increased at day 1 after angiography in control group (P < 0.01), the values of urinary α1 -MG, cystatin C and hsCRP still significantly increased at day 2 (P < 0.01) too, but those of TRF and mALB had no significantly change at day 1 or day 2 after angiography between the two groups (P > 0.05). There was no significant change in BUN, Cr, Ccr levels before and after angiography between the two groups. Conclusions Low dose contrast induces light renal function damage. Pretreatment with atorvastatin 20 mg/qn for 2 to 3 days could significantly reduce procedural inflammatory reaction, attenuate urinary protein and the effect of degrading GFR in coronary angiography patients. 相似文献
9.
阿托伐他汀改善对比剂对肾功能的短期影响 总被引:5,自引:1,他引:4
目的 观察阿托伐他汀对冠状动脉造影患者肾功能、尿微量蛋白及超敏C反应蛋白(hsCRP)改变的影响.方法 120例单纯冠状动脉造影的患者随机分为他汀组(60例)或对照组(60例),他汀组于冠状动脉造影术前2~3 d始每晚顿服阿托伐他汀20 mg,对照组未服用阿托伐他汀及其他调脂类药.所有患者分别于术前、术后第1天、第2天测定血清肌酐(Scr)及尿素氮(BUN);留尿标本检测尿α1-微球蛋白(α1-MG)、尿转铁蛋白(TRF)和尿微量白蛋白(mALB);测血浆胱抑素C(Cys C)、hsCRP,并根据Cockcrofi-Gauh公式和GFR(ml/min)=74.835/Cys C1.333公式分别计算出肌酐清除率(Ccr)和肾小球滤过率(GFR).结果 (1)对照组:与术前相比,术后第1天α1-MG、TRF、mALB、Cys C及hsCRP均有显著升高(P<0.01);与术后第1天比较,术后第2天α1-MG、TRF、mALB、Cys C均有显著降低(P<0.01),但α1-MG、Cys C仍高于术前水平(P<0.01),而TRF、mALB已恢复到术前水平(P>0.05);术后第2天hsCRP与术前第l天相比无明显变化(P>0.05).(2)他汀组:与术前比较,术后第1天及第2天α1-MG、TRF、mALB、Cys C均无明显变化(P>0.05);术后第1天hsCRP显著升高(P<0.01);术后第2天hsCRP与术前第1天相比无明显变化(P>0.05).(3)与他汀组相比较:对照组术后第1天α1-MG、TRF、mALB、Cys C及hsCRP均显著升高(P<0.01);术后第2天Cys C、α1-MG及hsCRP仍显著升高(P<0.01),但TRF、mALB均无统计学差异(P>0.05).两组术前、术后BUN、Scr、Ccr均无明显变化(P>0.05).结论 对比剂可造成轻微的一过性肾功能损害.阿托伐他汀于冠状动脉造影术前2~3 d给药,可能具有减轻炎症反应、改善患者一过性蛋白尿及GFR降低的作用,提示町能有预防对比剂肾病的作用. 相似文献
10.
Objective To study the effects of atorvastatin on contrast induced renal function change and plasma hsCRP in patients undergoing coronary angiography. Methods 120 patients who underwent coronary angiography were randomized to receive atorvastatin (20 mg/qn, n = 60) or no atorvastatin (n =60) treatment 2 to 3 days before coronary angiography. Urinary α1-MG, TRF and mALB were checked for evidence of tubular or glomendar damage at start, 1 day and 2 days after the administration of a radiocontrast agent. Serum creatinine, BUN, cystatin C and hsCRP levels were also assessed at the same time. Ccr and GFR were calculated according to Cockcroft-Ganh and GFR(ml/min) = 74. 835/Cys C1.333formulas basing on serum creatinine or cystatin C concentration. Results (1) In control group, comparison with the value before coronary angiography,urinary α1-MG, TRF and mALB or serum cystatin C and hsCRP significantly increased at day 1 after angiography (P < 0.01). In comparison to the levels at day 1 after angiography, urinary α1-MG, TRF, mALB, serum cystatin C significantly decreased at day 2 after angiography(P < 0.01), but α1-MG, cystatin C still exceeded the values before coronary angiography, TRF and mALB levels at day 2 after angiography had no significant change compared to baseline(P >0.05), hsCRP LeveL at day 2 after angiography had no significant change compared to that at day 1 after angiography (P > 0.05) too. (2) In comparison with the value before coronary angiography in atorvastatin-treated group, the levels of urinary α1-MG, TRF and mALB or serum cystatin C at day 1 and day 2 after angiography had no significant change compared to baseline(P >0.05). Serum hsCRP significantly increased at day 1 after angiography compared to baseline(P < 0.01), but it had no significant change compared to day 2 after angiography (P > 0.05). (3)To compare to the atorvastatin-treated group, the values of urinary α1-MG, TRF and mALB or Cys C and hsCRP significantly increased at day 1 after angiography in control group (P < 0.01), the values of urinary α1 -MG, cystatin C and hsCRP still significantly increased at day 2 (P < 0.01) too, but those of TRF and mALB had no significantly change at day 1 or day 2 after angiography between the two groups (P > 0.05). There was no significant change in BUN, Cr, Ccr levels before and after angiography between the two groups. Conclusions Low dose contrast induces light renal function damage. Pretreatment with atorvastatin 20 mg/qn for 2 to 3 days could significantly reduce procedural inflammatory reaction, attenuate urinary protein and the effect of degrading GFR in coronary angiography patients. 相似文献